Osama Hussein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Osama Hussein has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Adel Denewer
Surgical Oncology Department, Oncology Center, Mansoura University, Egypt
10 shared publications - Omar Farouk
Department of Surgical Oncology and Breast Surgery, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt
7 shared publications - Svetlana V. Komarova
Shriners Hospital for Children, Montreal, Canada
5 shared publications Kerstin Tiedemann
Faculty of Dentistry, McGill University, Montreal, QC, Canada
4 shared publicationsSameh Roshdy
Surgical Oncology Department, Mansoura University Faculty of Medicine, Mansoura University Cancer Center, Mansoura, Egypt
4 shared publications- Sherif Kotb
Unit of Surgical Oncology, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt
4 shared publications
Latest Publications
- 6 October 2026
- Published by Wiley in Molecular Carcinogenesis
Cooperative Modulation of the NF‐κB and p53 Pathways by Metronomic Cyclophosphamide and Metformin Inhibits Ehrlich Carcinoma Progression and Enhances Systemic Immunity
This study investigates the cooperative antitumor potential of combining metronomic cyclophosphamide (MTm‐CTX) with the metabolic modifier metformin (MET) in a murine model of mammary carcinoma. While metronomic chemotherapy offers a reduced toxicity profile, its efficacy as a monotherapy is often limited by compensatory inflammatory signaling. We hypothesized that metabolic intervention with metformin could sensitize tumor cells to metronomic dosing by modulating key survival and immune pathways. Using mice bearing Ehrlich solid carcinoma (ESC), we evaluated the effects of MTm‐CTX and MET, both individually and in combination, on tumor progression and the underlying molecular landscape. Our results demonstrate that the combination therapy significantly inhibits tumor growth, achieving a marked 65% reduction in tumor volume compared to the control group. Mechanistically, the combined regimen was associated with an apoptotic shift, characterized by the upregulation of p53 and the significant downregulation of survivin and Ki‐67 expression. Furthermore, the treatment effectively modulated the tumor microenvironment by suppressing NF‐κB, TNF‐α, and IL‐6 expression. Notably, this local tumor suppression is coupled with enhanced systemic cytotoxic immunity, marked by a significant upregulation of splenic Granzyme B alongside a numerical upward trend in interferon‐gamma (IFN‐γ) expression. Quantitative histopathological analysis confirmed substantial tumor regression and reduced viability in the combination group. These findings provide compelling evidence that the MTm‐CTX and MET combination acts through a coordinated alternation of apoptotic and immune‐inflammatory pathways. This study establishes a scientifically grounded framework for a potentially promising, cost‐effective, and low‐toxicity chemo‐metabolic strategy worthy of further exploration in breast cancer management.
- 6 October 2026
- Published by Wiley in Molecular Carcinogenesis
Cooperative Modulation of the NF‐κB and p53 Pathways by Metronomic Cyclophosphamide and Metformin Inhibits Ehrlich Carcinoma Progression and Enhances Systemic Immunity
This study investigates the cooperative antitumor potential of combining metronomic cyclophosphamide (MTm‐CTX) with the metabolic modifier metformin (MET) in a murine model of mammary carcinoma. While metronomic chemotherapy offers a reduced toxicity profile, its efficacy as a monotherapy is often limited by compensatory inflammatory signaling. We hypothesized that metabolic intervention with metformin could sensitize tumor cells to metronomic dosing by modulating key survival and immune pathways. Using mice bearing Ehrlich solid carcinoma (ESC), we evaluated the effects of MTm‐CTX and MET, both individually and in combination, on tumor progression and the underlying molecular landscape. Our results demonstrate that the combination therapy significantly inhibits tumor growth, achieving a marked 65% reduction in tumor volume compared to the control group. Mechanistically, the combined regimen was associated with an apoptotic shift, characterized by the upregulation of p53 and the significant downregulation of survivin and Ki‐67 expression. Furthermore, the treatment effectively modulated the tumor microenvironment by suppressing NF‐κB, TNF‐α, and IL‐6 expression. Notably, this local tumor suppression is coupled with enhanced systemic cytotoxic immunity, marked by a significant upregulation of splenic Granzyme B alongside a numerical upward trend in interferon‐gamma (IFN‐γ) expression. Quantitative histopathological analysis confirmed substantial tumor regression and reduced viability in the combination group. These findings provide compelling evidence that the MTm‐CTX and MET combination acts through a coordinated alternation of apoptotic and immune‐inflammatory pathways. This study establishes a scientifically grounded framework for a potentially promising, cost‐effective, and low‐toxicity chemo‐metabolic strategy worthy of further exploration in breast cancer management.
- Open Access
- 2 January 2024
- Published by Springer Nature in BMC Research Notes
- Vol. 17 (1) , 1-6
Metronomic cyclophosphamide and metformin inhibited tumor growth and repopulated tumor-infiltrating lymphocytes in an experimental carcinoma model
Metformin is a widely used antidiabetic biguanide. Retrospective data demonstrated the association of metformin use with survival benefit in multiple tumor types. Interest in repurposing metformin to treat cancer has not been translated into encouraging clinical benefit. In animal models, metformin activated cytotoxic T cells and exerted an immune-mediated anticancer effect. The current research was conducted to investigate the possible therapeutic benefit of metformin in combination with metronomic cyclophosphamide in an experimental cancer model. Ehrlich ascites carcinoma was injected into the subcutaneous tissue to induce solid tumors in syngeneic mice. Exponential solid tumor growth ensued and was effectively arrested with the administration of a cytotoxic dose of parenteral cyclophosphamide. Alternatively, oral metformin and continuous, low-dose cyclophosphamide significantly inhibited tumor growth relative to untreated mice. The drug combination was well tolerated. Histopathological examination of the tumor showed an increased number of tumor-infiltrating lymphocytes and enhanced expression of granzyme B by this drug combination. The current data suggests a potential role of metformin and metronomic chemotherapy that warrants further investigation.
- 2 January 2024
- Published by Springer Nature in BMC Research Notes
- Vol. 17 (1) , 1-6
Open AccessMetronomic cyclophosphamide and metformin inhibited tumor growth and repopulated tumor-infiltrating lymphocytes in an experimental carcinoma model
Metformin is a widely used antidiabetic biguanide. Retrospective data demonstrated the association of metformin use with survival benefit in multiple tumor types. Interest in repurposing metformin to treat cancer has not been translated into encouraging clinical benefit. In animal models, metformin activated cytotoxic T cells and exerted an immune-mediated anticancer effect. The current research was conducted to investigate the possible therapeutic benefit of metformin in combination with metronomic cyclophosphamide in an experimental cancer model. Ehrlich ascites carcinoma was injected into the subcutaneous tissue to induce solid tumors in syngeneic mice. Exponential solid tumor growth ensued and was effectively arrested with the administration of a cytotoxic dose of parenteral cyclophosphamide. Alternatively, oral metformin and continuous, low-dose cyclophosphamide significantly inhibited tumor growth relative to untreated mice. The drug combination was well tolerated. Histopathological examination of the tumor showed an increased number of tumor-infiltrating lymphocytes and enhanced expression of granzyme B by this drug combination. The current data suggests a potential role of metformin and metronomic chemotherapy that warrants further investigation.
- Open Access
- 27 September 2023
- Published by Springer Nature in Research Square
Metronomic cyclophosphamide and metformin inhibited tumor growth and repopulated tumor infiltrating lymphocytes in experimental carcinoma model
Metformin is a widely used antidiabetic biguanide. Retrospective data demonstrated the association of metformin use with survival benefit in multiple tumor types. Interest in repurposing metformin to treat cancer has not been translated into encouraging clinical benefit. In animal models, metformin activated cytotoxic T cells and exerted an immune-mediated anticancer effect. The current research was conducted to investigate the possible therapeutic benefit of metformin in combination with metronomic cyclophosphamide in an experimental cancer model. Ehrlich ascites carcinoma was injected into the subcutaneous tissue to induce solid tumors in syngeneic mice. Exponential solid tumor growth ensued and was effectively arrested with the administration of a cytotoxic dose of parenteral cyclophosphamide. Alternatively, oral metformin and continuous, low-dose cyclophosphamide significantly inhibited tumor growth relative to untreated mice. The drug combination was well tolerated. Histopathological examination of the tumor showed an increased number of tumor-infiltrating lymphocytes and enhanced expression of granzyme B by this drug combination. The current data suggests a potential role of metformin and metronomic chemotherapy that warrants further investigation.
- 27 September 2023
- Published by Springer Nature in Research Square
Open AccessMetronomic cyclophosphamide and metformin inhibited tumor growth and repopulated tumor infiltrating lymphocytes in experimental carcinoma model
Metformin is a widely used antidiabetic biguanide. Retrospective data demonstrated the association of metformin use with survival benefit in multiple tumor types. Interest in repurposing metformin to treat cancer has not been translated into encouraging clinical benefit. In animal models, metformin activated cytotoxic T cells and exerted an immune-mediated anticancer effect. The current research was conducted to investigate the possible therapeutic benefit of metformin in combination with metronomic cyclophosphamide in an experimental cancer model. Ehrlich ascites carcinoma was injected into the subcutaneous tissue to induce solid tumors in syngeneic mice. Exponential solid tumor growth ensued and was effectively arrested with the administration of a cytotoxic dose of parenteral cyclophosphamide. Alternatively, oral metformin and continuous, low-dose cyclophosphamide significantly inhibited tumor growth relative to untreated mice. The drug combination was well tolerated. Histopathological examination of the tumor showed an increased number of tumor-infiltrating lymphocytes and enhanced expression of granzyme B by this drug combination. The current data suggests a potential role of metformin and metronomic chemotherapy that warrants further investigation.
- Open Access
- 2 September 2022
- Published by Springer Nature in Research Square
Extended surgical resection for primary retroperitoneal sarcoma. Systematic review and meta- analysis
Background & Objectives: Retroperitoneal sarcomas are often advanced at presentation. Surgery remains the only available curative management. The extent of surgical resection is debatable. There is a strong cause for compartmental resection of the whole hemi-retroperitoneum, but high-level evidence is lacking. This systematic review examines published evidence for the effect of resection policy on the oncologic outcome.Methods: The PubMed was searched for “retroperitoneal neoplasms”, “surgery”, “surgical procedures, operative”, and “margin of resection”. Web Of Science™ was searched for “retroperitoneal neoplasms” and “surgical management”. English-language articles that investigated retroperitoneal sarcoma in adult patients with extent of surgery as an independent variable and oncologic outcome as endpoints were included.Results: Twenty-three articles were retained for analysis. All articles were retrospective. Meta-analysis showed equivalence of overall survival with extended surgery versus limited surgery and with sole tumor resection versusen-blocresection with contiguous organs. Multivisceral resection did not increase morbidity.Conclusions: The role of universal extended surgery and the subset of patients who may benefit from irradiation treatment remain open questions.
- 2 September 2022
- Published by Springer Nature in Research Square
Open AccessExtended surgical resection for primary retroperitoneal sarcoma. Systematic review and meta- analysis
Background & Objectives: Retroperitoneal sarcomas are often advanced at presentation. Surgery remains the only available curative management. The extent of surgical resection is debatable. There is a strong cause for compartmental resection of the whole hemi-retroperitoneum, but high-level evidence is lacking. This systematic review examines published evidence for the effect of resection policy on the oncologic outcome.Methods: The PubMed was searched for “retroperitoneal neoplasms”, “surgery”, “surgical procedures, operative”, and “margin of resection”. Web Of Science™ was searched for “retroperitoneal neoplasms” and “surgical management”. English-language articles that investigated retroperitoneal sarcoma in adult patients with extent of surgery as an independent variable and oncologic outcome as endpoints were included.Results: Twenty-three articles were retained for analysis. All articles were retrospective. Meta-analysis showed equivalence of overall survival with extended surgery versus limited surgery and with sole tumor resection versusen-blocresection with contiguous organs. Multivisceral resection did not increase morbidity.Conclusions: The role of universal extended surgery and the subset of patients who may benefit from irradiation treatment remain open questions.
- Open Access
- 1 June 2021
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 1105 (1) , 012034
LORA in a Campus: Reliability and Stability Testing
Long Range (LoRa) Technology offers robust wireless solutions for data collection and communication in smart buildings and smart cities by providing superior performance as a solution for the Internet of Things infrastructure. Its four powerful parameters usually govern the communication performance of LoRa; the transmit power, Spreading Factor (SF), Code Rate (CR), and the Bandwidth (BW). This work introduces a comprehensive study of LoRa’s behavior and the role of the abovementioned parameters based on experimental validation of the various performance metrics of LoRa. LoRa is tested to evaluate its reliability and stability in reality, where the different environment is adopted in Electrical Engineering Technical College in Baghdad, Iraq. In terms of LoRa reliability, the results show an acceptable Mean Absolute Error (MAE) equals to 11.33dB when comparing reference and experimental LoRa sensitivity for all SF values. Moreover, 18% of packet loss has resulted from a heavy fading environment with minimal power and SF. On the other hand, LoRa sensitivity test shows that the variance calculated for 200 RSS samples in a heavy fading condition equals 29.9064. Both tests quantify the efficiency of LoRa in such a harsh environment and pave the way for future LoRa applications implementation.
- 1 June 2021
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 1105 (1) , 012034
Open AccessLORA in a Campus: Reliability and Stability Testing
Long Range (LoRa) Technology offers robust wireless solutions for data collection and communication in smart buildings and smart cities by providing superior performance as a solution for the Internet of Things infrastructure. Its four powerful parameters usually govern the communication performance of LoRa; the transmit power, Spreading Factor (SF), Code Rate (CR), and the Bandwidth (BW). This work introduces a comprehensive study of LoRa’s behavior and the role of the abovementioned parameters based on experimental validation of the various performance metrics of LoRa. LoRa is tested to evaluate its reliability and stability in reality, where the different environment is adopted in Electrical Engineering Technical College in Baghdad, Iraq. In terms of LoRa reliability, the results show an acceptable Mean Absolute Error (MAE) equals to 11.33dB when comparing reference and experimental LoRa sensitivity for all SF values. Moreover, 18% of packet loss has resulted from a heavy fading environment with minimal power and SF. On the other hand, LoRa sensitivity test shows that the variance calculated for 200 RSS samples in a heavy fading condition equals 29.9064. Both tests quantify the efficiency of LoRa in such a harsh environment and pave the way for future LoRa applications implementation.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Breast Cancer: Basic and Clinical Research
- Vol. 15
High Seroprevalence of Hepatitis C Virus Antibody in Breast Cancer Patients in Egypt
Hepatitis C virus (HCV) is a known risk factor for hepatocellular carcinoma. Several epidemiological studies have pointed out to an association of HCV infection with other extrahepatic malignancies. The role of chronic HCV in breast cancer causation is less clear. Egypt is an endemic area of HCV infection with resulting significant morbidity. The association between HCV status and breast cancer risk in Egyptian women is hitherto unknown. A retrospective study was performed. The prevalence of anti-HCV seropositivity was estimated in a sample of women with a breast cancer diagnosis, retrieved from the hospital records, and was compared to the raw data of a population study in Egypt. Anti-HCV negative and positive patients were compared regarding the disease course and outcome. Retrospective analysis revealed a markedly high prevalence of anti-HCV seropositivity in young breast cancer patients. In patients younger than 45 years, 13.4% were anti-HCV positive. Seropositivity was 6-fold higher in these patients than in adult females of the same age without cancer diagnosis (P = .003). The biological type, tumor size, nodal status, and disease-free survival were not affected by the patients’ HCV status. Young Egyptian breast cancer patients have a dramatically high prevalence of HCV seropositivity. Further population studies are strongly required to investigate the epidemiological association of these two significant health problems.
- 1 January 2021
- Published by SAGE Publications in Breast Cancer: Basic and Clinical Research
- Vol. 15
Open AccessHigh Seroprevalence of Hepatitis C Virus Antibody in Breast Cancer Patients in Egypt
Hepatitis C virus (HCV) is a known risk factor for hepatocellular carcinoma. Several epidemiological studies have pointed out to an association of HCV infection with other extrahepatic malignancies. The role of chronic HCV in breast cancer causation is less clear. Egypt is an endemic area of HCV infection with resulting significant morbidity. The association between HCV status and breast cancer risk in Egyptian women is hitherto unknown. A retrospective study was performed. The prevalence of anti-HCV seropositivity was estimated in a sample of women with a breast cancer diagnosis, retrieved from the hospital records, and was compared to the raw data of a population study in Egypt. Anti-HCV negative and positive patients were compared regarding the disease course and outcome. Retrospective analysis revealed a markedly high prevalence of anti-HCV seropositivity in young breast cancer patients. In patients younger than 45 years, 13.4% were anti-HCV positive. Seropositivity was 6-fold higher in these patients than in adult females of the same age without cancer diagnosis (P = .003). The biological type, tumor size, nodal status, and disease-free survival were not affected by the patients’ HCV status. Young Egyptian breast cancer patients have a dramatically high prevalence of HCV seropositivity. Further population studies are strongly required to investigate the epidemiological association of these two significant health problems.
- 1 November 2020
- Published by Elsevier in Medical Hypotheses
- Vol. 144, 110238
Second wave of Covid-19 is determined by immune mechanism
- 1 November 2020
- Published by Elsevier in Medical Hypotheses
- Vol. 144, 110238
Second wave of Covid-19 is determined by immune mechanism
- Open Access
- 5 June 2020
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 8, 435
Role of Altered Metabolic Microenvironment in Osteolytic Metastasis
Metastatic bone disease is generally incurable and leads to pathological fractures, pain, hypercalcemia, spinal cord compression and decreased mobility. The skeleton is the major site of bone metastases from solid cancers, including breast and prostate carcinoma. Bone metastasis is facilitated by activation of bone-resorbing osteoclasts, terminally differentiated multinucleated cells formed by fusion from monocytic precursors. Cancer cells are known to produce specific factors that stimulate osteoclast differentiation and function. Of interest, cancer cells are also known to alter their own bioenergetics increasing the use of glycolysis for their survival and function. Such change in energy utilization by cancer cells would result in altered levels of cell-permeable metabolites, including glucose, lactate, and pyruvate. Osteoclast resorption is energy-expensive, and we have previously demonstrated that during differentiation osteoclasts actively adapt to their bioenergetics microenvironment. We hypothesize that altered bioenergetics state of cancer cells will also modify the bioenergetics substrate availability for the tissue-resident bone cells, potentially creating a favorable milieu for pathological osteolysis. The goals of this review are to analyze how metastasizing cancer cells change the availability of energy substrates in bone microenvironment; and to assess how the altered bioenergetics may affect osteoclast differentiation and activity.
- 5 June 2020
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 8, 435
Open AccessRole of Altered Metabolic Microenvironment in Osteolytic Metastasis
Metastatic bone disease is generally incurable and leads to pathological fractures, pain, hypercalcemia, spinal cord compression and decreased mobility. The skeleton is the major site of bone metastases from solid cancers, including breast and prostate carcinoma. Bone metastasis is facilitated by activation of bone-resorbing osteoclasts, terminally differentiated multinucleated cells formed by fusion from monocytic precursors. Cancer cells are known to produce specific factors that stimulate osteoclast differentiation and function. Of interest, cancer cells are also known to alter their own bioenergetics increasing the use of glycolysis for their survival and function. Such change in energy utilization by cancer cells would result in altered levels of cell-permeable metabolites, including glucose, lactate, and pyruvate. Osteoclast resorption is energy-expensive, and we have previously demonstrated that during differentiation osteoclasts actively adapt to their bioenergetics microenvironment. We hypothesize that altered bioenergetics state of cancer cells will also modify the bioenergetics substrate availability for the tissue-resident bone cells, potentially creating a favorable milieu for pathological osteolysis. The goals of this review are to analyze how metastasizing cancer cells change the availability of energy substrates in bone microenvironment; and to assess how the altered bioenergetics may affect osteoclast differentiation and activity.
- Open Access
- 17 January 2020
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 32 (1) , 1-4
Thyroid cancer associated with Hashimoto thyroiditis: similarities and differences in an endemic area
Background: Hashimoto thyroiditis (HT) is an autoimmune lymphocytic thyroiditis and is the most common form of thyroid inflammatory diseases. The association of HT with papillary thyroid carcinoma (PTC) has been described. PTC is the most common form of malignancy associated with HT. When papillary carcinoma develops on top of Hashimoto thyroiditis, the disease tends to be less aggressive and lymph node and extra-thyroidal invasion are infrequent. Results: We retrospectively examined the pathological features of our patients who were diagnosed with concomitant HT and thyroid cancer. In Egyptian patients, PTC was the main type of malignancy associated with HT (96.2%) and was often multifocal (46.2%). In contrast to the published literature, lymph node invasion and extra-thyroidal extension were as frequent in association with HT as in other cancer cohorts. We also observed the frequent occurrence of Hürthle cell metaplasia (23.1%) and the appreciable incidence of aggressive histological types of PTC (32%). Conclusion: Thyroid carcinoma with HT may have some aggressive features in areas with endemic goiter background.
- 17 January 2020
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 32 (1) , 1-4
Open AccessThyroid cancer associated with Hashimoto thyroiditis: similarities and differences in an endemic area
Background: Hashimoto thyroiditis (HT) is an autoimmune lymphocytic thyroiditis and is the most common form of thyroid inflammatory diseases. The association of HT with papillary thyroid carcinoma (PTC) has been described. PTC is the most common form of malignancy associated with HT. When papillary carcinoma develops on top of Hashimoto thyroiditis, the disease tends to be less aggressive and lymph node and extra-thyroidal invasion are infrequent. Results: We retrospectively examined the pathological features of our patients who were diagnosed with concomitant HT and thyroid cancer. In Egyptian patients, PTC was the main type of malignancy associated with HT (96.2%) and was often multifocal (46.2%). In contrast to the published literature, lymph node invasion and extra-thyroidal extension were as frequent in association with HT as in other cancer cohorts. We also observed the frequent occurrence of Hürthle cell metaplasia (23.1%) and the appreciable incidence of aggressive histological types of PTC (32%). Conclusion: Thyroid carcinoma with HT may have some aggressive features in areas with endemic goiter background.
- Open Access
- 5 February 2018
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 5, 3
Parotid Quadrantectomy Is a Safe Management for Localized Pleomorphic Adenoma
Aim: Pleomorphic adenoma is the most common benign tumor of the parotid gland and is classically treated with superficial or total parotidectomy. Less radical surgeries have been proposed to minimize the risk of facial nerve injury. The oncological safety of these procedures remains controversial. We conducted this study to evaluate the safety of superficial hemi-lobectomy (quadrantectomy). Patients and methods: Retrospective analysis was conducted on the paraffin sections of archived superficial parotidectomy specimens from 11 male and 6 female patients (median age 33 years). The microscopic extent of extra-capsular extension was determined on pathological revision. In addition, prospective evaluation of 12 quadrantectomy procedures (M/F = 7/5, median age = 36 years) compared to 24 radical surgeries (M = F, median age = 40 years) regarding temporary and persistent facial nerve dysfunction on routine clinical assessment and recurrence rate. Results: On retrospective pathological revision, pleomorphic adenomata had a median microscopic spread of 3 mm beyond capsule in paraffin sections (SD = 3.6). On prospective analysis with a median follow-up of 33 months (range = 18–54 months), quadrantectomy had similar relative risk of temporary facial nerve dysfunction evaluated at the immediate postoperative period as well as persistent nerve dysfunction assessed at 3 months (P = 0.701 and P = 0.902, respectively). Of the whole study population, one case of recurrence after total parotidectomy was observed at mid-term follow-up (P = 1.000). Conclusion: Parotid quadrantectomy is a safe management for smaller pleomorphic adenomata localized close to one of the two divisions of the facial nerve.
- 5 February 2018
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 5, 3
Open AccessParotid Quadrantectomy Is a Safe Management for Localized Pleomorphic Adenoma
Aim: Pleomorphic adenoma is the most common benign tumor of the parotid gland and is classically treated with superficial or total parotidectomy. Less radical surgeries have been proposed to minimize the risk of facial nerve injury. The oncological safety of these procedures remains controversial. We conducted this study to evaluate the safety of superficial hemi-lobectomy (quadrantectomy). Patients and methods: Retrospective analysis was conducted on the paraffin sections of archived superficial parotidectomy specimens from 11 male and 6 female patients (median age 33 years). The microscopic extent of extra-capsular extension was determined on pathological revision. In addition, prospective evaluation of 12 quadrantectomy procedures (M/F = 7/5, median age = 36 years) compared to 24 radical surgeries (M = F, median age = 40 years) regarding temporary and persistent facial nerve dysfunction on routine clinical assessment and recurrence rate. Results: On retrospective pathological revision, pleomorphic adenomata had a median microscopic spread of 3 mm beyond capsule in paraffin sections (SD = 3.6). On prospective analysis with a median follow-up of 33 months (range = 18–54 months), quadrantectomy had similar relative risk of temporary facial nerve dysfunction evaluated at the immediate postoperative period as well as persistent nerve dysfunction assessed at 3 months (P = 0.701 and P = 0.902, respectively). Of the whole study population, one case of recurrence after total parotidectomy was observed at mid-term follow-up (P = 1.000). Conclusion: Parotid quadrantectomy is a safe management for smaller pleomorphic adenomata localized close to one of the two divisions of the facial nerve.